Abstract:Background Phantoms are commonly used to evaluate and compare the performance of imaging systems given the known ground truth. Positron emission tomography (PET) scanners are routinely validated using the NEMA image quality phantom, in which lesions are modeled using 10 to 37 mm fillable spheres. The NEMA phantom neglects, however, to model focal (3–10‐mm), high‐uptake lesions that are increasingly observed in prostate‐specific membrane antigen (PSMA) PET images. PSMA‐targeting radiopharmaceuticals allow for enhanced detection of metastatic prostate cancers. As such, there is significant need to develop an updated phantom which considers both the quantitative and lesion detectability of this new paradigm in oncological PET imaging. Purpose In this work, we present the Quantitative PET Prostate Phantom (Q3P); a portable and modular phantom that can be used to improve and harmonize imaging protocols for 18F‐PSMA PET scans. Methods A one‐piece cylindrical phantom was designed effectively in two halves, which we call modules. Module 1 was designed to mimic lesions in the presence of background, and Module 2 mimicked very high contrast conditions (i.e., very low background) that can be observed in 18F‐PSMA PET scans. Shell‐less radioactive spheres (3–16‐mm) were cast using epoxy resin mixed with sodium‐22 (22Na), a long half‐life positron emitter with positron range similar to 18F. To establish realistic lesion contrast, the 22Na spheres were mounted in a cylindrical chamber that can be filled with an 18F background (module 1). Thirteen exchangeable spherical cavity inserts (3–37‐mm) were machined in two parts and solvent welded together, and filled with 18F (50 kBq/mL) to model lesions with very high contrast (module 2). Five 2.5‐min PET scans were acquired on a 5‐ring GE Discovery MI PET/CT scanner (General Electric, USA). Lesions were segmented using 41% of SUVmax fixed thresholding (41% FT) and recovery coefficients (RCs) were computed from 5 noise realizations. Results The manufactured phantom is portable (5.7 kg) and scan preparation takes less than 40 min. The total 22Na activity is 250 kBq, allowing it to be shipped as an exempt package under International Atomic Energy Agency (IAEA) regulations. Recovery coefficients, computed using PSF modeling and no post‐reconstruction smoothing, were 130.3% (16 mm), 147.1% (10 mm), 87.2% (6 mm), and 7.0% (3 mm) for RCmax, which decreased to 91.1% (16 mm), 90.6% (10 mm), 53.2% (6 mm), and 3.6% (3 mm) for RCmean in the 22Na spheres. Comparatively, 18F sphere recovery was 110.7% (17 mm), 123.6% (10 mm), 106.5% (7 mm), and 23.3% (3 mm) for RCmax, which was reduced to 76.7% (17 mm), 77.7% (10 mm), 66.8% (7 mm), and 13.5% (3 mm), for RCmean. Conclusions A standardized imaging phantom was developed for lesion quantification assessment in 18F‐PSMA PET images. The phantom is configurable, providing users with the opportunity to modify background activity levels or sphere sizes according to clinical demands. Distributed to the community, the Q3P phantom has the potential to enable better assessment of lesion quantification and harmonization of 18F‐PSMA PET imaging, which may lead to more robust predictive metrics and better outcome prediction in metastatic prostate cancer.

Development of a novel phantom for tau PET imaging

Simulation study of a brain PET scanner using TOF-DOI detectors equipped with first interaction position detection.

PICASSO: a universal brain phantom for positron emission tomography based on the activity painting technique

International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer’s disease

Development and Evaluation of a New High-Tof-resolution All-Digital Brain PET System.

Sub-Detector Unit Timing Calibration for Brain Pet Based on L1-Norm Constraint

Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease

Optimization and Biodistribution of [11C]-TKF, an Analog of Tau Protein Imaging Agent [18F]-THK523

Spatial normalization and quantification approaches of PET imaging for neurological disorders

TauPETGen: Text-Conditional Tau PET Image Synthesis Based on Latent Diffusion Models

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Perception-Enhanced Generative Adversarial Network for Synthesizing Tau Positron Emission Tomography images from Structural Magnetic Resonance Images: a cross-center and cross-tracer study

Kinetic modeling of 18F-PI-2620 binding in the brain using an image-derived input function with total-body PET

Development of the quantitative PET prostate phantom (Q3P) for improved quality assurance of 18F‐PSMA PET imaging in metastatic prostate cancer

Performance evaluation of a high-resolution brain PET scanner using four-layer MPPC DOI detectors

Technical Note: Development of a 3D printed subresolution sandwich phantom for validation of brain SPECT analysis

Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model

The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease

Quantitative PET/CT scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom

PET/CT Alignment Calibration with a Non-Radioactive Phantom and the Intrinsic 176lu Radiation of PET Detector

Simulation of a Compton-based detector for low-dose high-resolution time-of-flight positron emission tomography